EZH2 and lymphoma: Given these findings, our objective was to evaluate and compare the inhibitory effects of two drugs: the EZH2 inhibitor Tazemetostat (referred to as iEZH2) and the novel PROTAC-based degrader MS1943 (referred to as dEZH2), on different types of lymphoma cells.